Novo Nordisk’s Phase 3 REDEFINE 1 study results for CagriSema have sparked a mixed reaction, with the drug achieving a 22.7% weight loss at 68 weeks, slightly edging out Lilly’s Zepbound at 22.5%.

Novo Nordisk faces challenges but its pipeline remains strong. Find out why NVO stock could deliver high double-digit returns ...

Novo Nordisk is facing serious pressure from a powerful ... whether the stock is still worth buying for a long-term hold. The bull thesis isn't what it used to be Novo is currently in a golden ...

I’m cautious about Novo Nordisk's stock in the short term due ... This is the case for both bull runs and selloffs. Considering that insiders haven't bought shares during the dip and some ...

We came across a bullish thesis on Novo Nordisk A/S (NVO) on Long-Term Pick’s Substack by Dan. In this article, we will summarize the bulls’ thesis on NVO. Novo Nordisk A/S (NVO)'s share was ...